Might gluten traces in wheat substitutes pose a risk in patients with celiac disease? A population-based probabilistic approach to risk estimation

Associació de Celíacs de Catalunya, Barcelona, Spain.
American Journal of Clinical Nutrition (Impact Factor: 6.77). 11/2012; 97(1). DOI: 10.3945/ajcn.112.047985
Source: PubMed


BACKGROUND: In patients with treated celiac disease (CD), the ingestion of gluten traces contained in gluten-free (GF) wheat substitutes (eg, GF bread, flour, and pasta) could cause persisting intestinal mucosal damage. OBJECTIVE: The objective was to evaluate the proportion of CD patients at risk of mucosal damage due to the consumption of GF products in 4 European countries (Italy, Spain, Germany, and Norway). DESIGN: A probabilistic modeling approach was used to assess the risk of gluten intake at the population level. The input variables were 1) consumption of GF products, 2) concentration of gluten traces in GF products determined by the sandwich R5 ELISA method, and 3) the gluten threshold for mucosal damage of 10 to 50 mg/d. Different population and product availability scenarios were examined for risk assessment. RESULTS: The gluten content of 205 commercially available GF products ranged between <5 and 27.8 mg/kg. Overall, 99.5% of the analyzed samples had a gluten concentration <20 mg/kg. Most (94%) had a gluten concentration below the limit of quantification (5 mg/kg). The mean percentage of the CD European population at risk of mucosal damage resulting from consumption of GF products ranged between 0.01 (Germany) and 0.15 (Italy) and remained very low, even in the worst-case scenario (<1%). CONCLUSIONS: The adoption of a single gluten threshold (20 mg/kg) for gluten contamination is suggested. GF products in Europe constitute a very safe option for patients with CD. The dietary follow-up of CD patients should focus on other potential sources of gluten contamination.

Download full-text


Available from: Alessio Fasano, Jan 06, 2014
    • "Among the most popular gluten-free products at the supermarket are bread, pasta, pastry, biscuits, crackers, pizza, pies, cakes and breakfast cereals. These products are safe for those with celiac disease and available in European countries as Italy, Spain, Germany and Norway (Gibert et al. 2013), Canada and the USA (Sloan 2011, 2014). However, just three years ago, the availability of these products was limited and more expensive than their counterparts; in London, only regular supermarkets and health food shops stocked such products (Singh & Whelan 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this chapter, we present the advances of enzymatic modification of gluten proteins and starches for gluten-free and low-glycaemic-index cereal foods. We also describe general information on wheat constituents which induce or trigger some diseases, their pathogenesis and the possible effects of these modified ingredients or foods.
    Advances in Food Biotechnology, First Edition edited by Ravishankar Rai V, 01/2015: chapter Enzymatic Modification of Proteins and Starches for Gluten-Free and Low-Glycaemic-Index Foods for Special Dietary Uses: pages 133-144; John Wiley & Sons, Ltd.., ISBN: 978-1-118-86455-5

  • American Journal of Clinical Nutrition 12/2012; 97(1). DOI:10.3945/ajcn.112.053777 · 6.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Celiac disease (CD) is an immune-mediated systemic condition triggered by dietary gluten occurring in genetically susceptible individuals. Our understanding of its numerous and varied clinical presentations has evolved over time, which has contributed to the incidence of CD increasing. In most cases, the diagnosis is readily established and patients promptly improve after commencing a gluten-free diet (GFD). However, in some, the diagnosis is not straightforward and presents a challenge to clinicians. Potential dilemmas include those with positive serology but normal histology, negative serology but abnormal duodenal mucosal histology, failure to respond to a GFD or response to a GFD without evidence of CD. In recent years, development of new assays and modifications to existing diagnostic algorithms for CD has also challenged the traditional role of small-bowel histology as critical in CD diagnosis.
    Expert review of gastroenterology & hepatology 09/2013; 7(7):643-55. DOI:10.1586/17474124.2013.834125 · 2.42 Impact Factor
Show more